

## CURRICULUM VITAE ANDREA DE CENSI, MD



### 1. General Information

Name	<b>Andrea De Censi</b>
Date and place of birth	April 19, 1958 in Biella, Italy
Marital status	Married with Gabriella; four children
Nationality	Italian
Working address	Division of Medical Oncology E.O. Ospedali Galliera Mura delle Cappuccine, 14 16128 Genoa, Italy Tel: +39-010-5634501 Fax: +39-010-57481090 Cell.:+39-320-4309396
e-mail:	<a href="mailto:andrea.decensi@galliera.it">andrea.decensi@galliera.it</a>
Home address	

### 2. Education

1987	Specialization in Medical Oncology, Postgraduate Medical School, University of Genoa
1984	Degree in Medicine and Surgery, Medical School, University of Pavia (first class honors)
1977	School Leaving Certificate (Scientific Lyceum), S. Donato Milanese, Milan

### **3.Certifications and Qualifications**

- 2013- 2017            National Scientific Qualification as University Full Professor issued by ANVUR (National Agency for the Evaluation of Universities and Research Institutes), an affiliate of ENQA (European Association for Quality Assurance in Higher Education).
- 2014-2017            Honorary Professor, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry
- 2008-2013            European Society of Medical Oncology (ESMO), Board Certificate in Medical Oncology
- 1984-                    License for medical practice

### **4.Honors and Awards**

- July 28, 2010            11<sup>th</sup> Annual advances in Cancer Prevention Lecture – “The future of cancer prevention clinical research”, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, USA
- August 18, 2011      1<sup>st</sup> Karen Johnson Memorial Lecture on Breast Cancer Prevention at the National Cancer Institute, Bethesda, USA: “Metformin for cancer prevention. Review of the evidence and future perspectives.”

### **5.Professional Employment (Clinical and Research Activities)**

- 2014-2017            Honorary Professor, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Barts & The London School of Medicine and Dentistry
- 2004-Today            Director, Division of Medical Oncology, Ospedali Galliera, Genoa
- 2004-Today            Scientific Consultant, Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan
- 2001-2003            Director, Division of Chemoprevention, European Institute of Oncology, Milan
- 1998-2001            Chief, Chemoprevention Unit, European Institute of Oncology, Milan
- 1995-1998            Assistant Director, Chemoprevention Unit, European Institute of Oncology, Milan
- 1994-1995            Deputy Chief, Department of Medical Oncology II  
National Institute for Cancer Research, Genoa

- 1993-1995      Consultant Oncologist at the Division of Urology, Nervi and Gallino Hospitals,  
ASL 3, Genoa
- 1988-1995      Consultant Oncologist at the University Department of Urology,  
San Martino General Hospital, Genoa
- 1988-1994      Tenured Assistant Oncologist at the Department of Medical Oncology II,  
National Institute for Cancer Research, Genoa
- 1985-1988      Fellow in Medical Oncology, University of Genoa, National Cancer Institute
- 1984-1985      Fellow in Medical Oncology, Fondazione Salvatore Maugeri, Pavia

## 5.1 SUMMARY OF SCIENTIFIC AND CLINICAL ACTIVITY

Dr. Andrea De Censi heads the Division of Medical Oncology at the Galliera Hospital, with 22 beds for Daily Hospital treatment and prolonged admission and 5 ambulatory rooms. His staff is formed by 8 medical oncologists, 9 nurses, 2 patient managers, 1 division's secretary, 6 research personnel including study coordinators, pharmacists and biologists.

His main clinical activity is devoted to the treatment of patients with all kind of solid tumors, with special interest to breast, colon, prostate, ovarian cancers and eye melanoma.

Dr. Andrea De Censi is a recognized expert in cancer chemoprevention. Through his seminal work in breast cancer chemoprevention, he founded with Prof. Umberto Veronesi and Dr. Alberto Costa the first Clinical Unit of Cancer Chemoprevention in Italy at the European Institute of Oncology in 1995, since then mentoring many young clinicians and scientists to develop this growing branch of medical oncology.

**He is author of 195 publications in peer-reviewed Journals, mostly as first or senior author, with a H-index of 43 and cumulative IF of approximately 1240.**

He has been awarded as Principal Investigator of over 25 no-profit clinical trials sponsored by different National and International Agencies or Charities, including the US-National Cancer Institute, the Susan G Komen Foundaation, the European Union, The Italian Ministry of Health, the Italian Association for Cancer Research (AIRC), the Italian League against Cancer (LILT), the Umberto Veronesi Foundation, the Guido Berlucci Foundation and the Avon Foundation, with a total amonunt of funding to the Applicant Institution through competitive grants of 8,065 M €.

He has been holder of a Master Agreement with the US National Cancer Institute for the conduction of phase I and phase II clinical prevention trial for the years 2004-today.

He is expert member of the working team: "Public Health Genomics" established within the Italian Ministry of Health and of WP 5 Writing Group "Public Health Genomics in Cancer" CANCON -EU Joint Action on Cancer Control.

He has served as member of several Committees for Cancer Prevention in the most important scientific associations, including:

- ASCO Cancer Prevention Committee, Member 2010-12
- Scientific Program Committee of the AACR International Conference on Frontiers in Cancer Prevention Research, 2011 and 2012
- Cancer Prevention Working group of the European Society of Clinical Oncology, 2008-today

He is corresponding member of the American Association for Cancer Research and the American Society of Clinical Oncology.

As regards his educational and teaching activities, he lectured from 1988-1991 at the Postgraduate Medical School of Oncology in Genoa and since 1995 at the Continuing Medical Education Program of

the European Institute of Oncology, Milan. He chaired the prevention session at the Master Course in Breast Cancer of the School of Medicine at the University of Milan in 2002 and 2003.

He is reviewer for several international Journals and from 2005 to 2007 he was member of the Editorial Board of the Journal of Clinical Oncology. Since 2014 he has been member of the Editorial Board of Cancer Prevention Research (CaPR).

As regards administrative activities, he worked from 1985 to 1991 in the scientific secretariat of the National Prostate Cancer Project in Genoa. From 2000 to 2010 he was member and served as secretary of the Scientific Committee of the Italian League against Cancer in Rome. From 2000 to 2001 he served as Member of the National Oncology Board appointed by the Health Minister. He

## **5.2. Time/effort of weekly activity in percentage:**

Clinical Care	50%
Research	30%
Administration	10%
Teaching/Mentoring	10%

## **6. Recent Invited Lecture (selected)**

2015	Magistral Lecture on Breast Cancer Prevention, Pisa, March 2015
2014	Metformin in breast cancer. Workshop at the 2014 AACR Prevention Meeting, New Orleans, Sept 2014 16th Milan Breast Cancer Conference
2013	15 <sup>th</sup> Milan Breast Cancer Conference Aspirin Foundation Scientific Conference, Oxford, UK
2012	ASCO Annual Meeting AACR Annual Meeting AACR Frontiers in Cancer Prevention Research 14 <sup>th</sup> Milan Breast Cancer Conference ESMO Annual Meeting
2011	ASCO annual meeting 13 <sup>th</sup> Milan Breast Cancer Conference AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications
2010	ASCO annual meeting 12 <sup>th</sup> Milan Breast Cancer Conference AACR Frontiers in Cancer Prevention Research

## **7. Teaching and Mentoring:**

From 2009 he has been supervising the monthly rotation of Genoa University Students in General Internal Medicine Specialty training at the Medical Oncology Division.

From 2004 he has trained in clinical research in oncology the following study coordinators:

- Daniela Branchi

- Domenico Marra
- Sara Campora
- Davide Corradengo
- Marilena Petretera
- Eleonora Campazzi
- Silvia Caviglia

He mentored the following young investigators:

- Dr. Nicoletta Provinciali, medical oncologist, 2013-2015
- Dr. Carlotta Defferrari, MD, medical oncologist, 2010-2014
- Dr. Mara Cafferata, medical oncologist, 2006-2009
- Dr. Alessandra Argusti 2004-2006
- Dr. Matteo Puntoni 2005-2010
- Dr. Massimo Cazzaniga, MD, preventive oncologist, 1998-2000
- Dr. Davide Serrano, MD, medical oncologist, 2000-2002
- Dr. Harriet Johansson, PhD in endocrinology oncology, 1998-2000
- Dr. Fredrick Marriett, PhD in endocrinology oncology, 2000-2002
- Dr. Aliana Guerrieri-Gonzaga, PhD in preventive oncology, 1996 -1998.
- Dr. Clara Varricchio, MD, preventive oncologist, 2002-2003.
- Dr. Francesca Pigatto, medical geneticist, 2003-2004
- Dr. Alessandra Pallucca, medical oncologist, 2000-2001
- Dr. Stefania Rapisardi, medical oncologist, 2003
- Dr. Arianna Galli, genetic counselor, 2001-2004
- Dr. Silvia Diani, genetic counselor, 1998-2001
- D. Paolo Manetti, preventive oncologist, 1999-2000
- Dr. Gabriel Farante, preventive oncologist, 1998

## **8. Teaching and Research Experience in Foreign Institutions**

- From August 17 to September 11, 2015. Visiting Professor at Institute of Preventive Medicine, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Chief Prof. Jack Cuzick, John Snow Professor of Epidemiology, Head, Centre for Cancer Prevention, Director, Wolfson Institute of Preventive Medicine.
- From July 15 to August 30, 1999. Visiting Professor at Memorial Sloan-Kettering Cancer Center, New York. Clinical Genetics Service, Chief Dr. Kenneth Offit; Clinical Director: Dr. Mark E Robson, Breast Surgery Unit, dr Patrick Borgen; Division of Medical Oncology, dr Larry Norton.
- From June 21 to July 5, 2001. Visiting Professor at MSKCC, NY, Breast Surgery Unit, dr Virgilio Sacchini; Medical Oncology, dr Clifford Hudis.
- From August 7 to 28, 2003. Visiting Professor at MSKCC, NY, Breast Surgery Unit, dr Virgilio Sacchini; Medical Oncology, dr Clifford Hudis.
- From July 27 to 29, 2010. Visiting Professor at the Division of Cancer Prevention, Director: dr. Peter Greenwald, NCI, Bethesda.

- From August 1 to August 31, 2011. Visiting Professor at the Division of Cancer Prevention, Director: dr. Barry Kramer, NCI, Bethesda

### **9.Extramural responsibilities**

- 2014-2017 Honorary Professor, Queen Mary University of London within the Wolfson Institute of Preventive Medicine and the Barts & The London School of Medicine and Dentistry: Collaboration with Prof Jack Cuzick and his team to conduct clinical trials in the adjuvant treatment of breast cancer and the preventive therapy of different cancers. Writing grant application.
- 2004-2016 Scientific advisor, Scientific Consultant, Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan: Strategic planning, design and overview of clinical trials; data analysis and publications.
- 2015-16 Expert member nominated by AIFA of the Superior Health Council sub committee on “Genomics in public health”.

#### **9.1 Journal peer review (ad hoc):**

Annals of Oncology  
Breast Cancer Research and Treatment  
BMJ  
Cancer Epidemiology Biomarkers and Prevention  
Cancer Research  
Clinical Cancer Research  
Clinical Reviews in Oncology/Hematology  
European Journal of Cancer  
International Journal of Cancer  
Journal of Clinical Oncology  
Journal of National Cancer Institute  
Lancet  
Nature Clinical Practice Oncology  
Science Translational Medicine

#### **9.2 Study sections:**

Italian League for Cancer Research (AIRC)  
European Organization for Research and Treatment of Cancer (EORTC)  
Cancer Research UK  
Dutch Cancer Research  
Slovenian Research Agency  
V Programma Quadro, European Union

## 10. List of Research Projects as Principal Investigator.

### 10.1 ACADEMIC TRIALS, STUDY PI

---

Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy . (Call for Proposals 2014)  
Project Coordinator Andrea DeCensi, E.O.Ospedali Galliera, Genova-Italy DeCensi P.I., 2014-2017;

- "A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colorectal advanced adenoma or cancer."

Total amount: 332.000€

Sponsor: European Research Area (ERA)-NET on Translational Cancer Research (TRANSCAN) (JTC 2013) .Project Coordinator Andrea DeCensi, E.O.Ospedali Galliera, Genova-Italy. DeCensi P.I., 2014-2017;

- "A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients." CANCER13-FP-056

Total amount: 1.342.550€

Sponsors: Umberto Veronesi Foundation (FUV) Milano-Italy; Indena S.p.A. Milano-Italy; Scientific Committee E.O.Ospedali Galliera, Genova-Italy. DeCensi (PI), 2011-on going

- "Randomized window of opportunity trial of anthocyanins and curcumin versus placebo in subjects with colorectal adenoma. The MIRACOL Study".

Patients enrolled: 16 Participating centers activation is on going.

Total amount: 230.000€

Sponsor: Italian Ministry of Health, Roma-Italy

DeCensi (PI- Operative Unit), 2009-2011

- A Pre-Surgical Phase II Study On Activity Of Metformin On Breast Cancer Cells Proliferation. RF2009-1532226

Total amount: 27.777,00 €

Sponsor: Italian Ministry of Health, Roma-Italy; Italian Association for Cancer Research (AIRC), Milano-Italy DeCensi (PI) 2008-2012

- Phase III study of low dose tamoxifen in women with breast intraepithelial neoplasia.

Total amount: 521.143,88 €

Sponsor: Italian League against Cancer (LILT), Roma-Italy

DeCensi (PI), 2008-2012

- "CYP2D6 genotype and tamoxifen response in women with breast intraepithelial neoplasia"

Total amount: 50.030,00 €

Sponsor: Berlucci Foundation, Brescia-Italy; Italian League against Cancer (LILT), Roma-Italy

DeCensi (PI), 2008

- Prevention of prostate cancer with a weekly administration of bicalutamide in subjects with elevated PSA and negative biopsy. The WEB study



Total amount: 290.000 €

Sponsor: European Institute of Oncology Milan-Italy  
DeCensi(PI), 2006-2011

- A phase II study of gw572016 (Lapatinib <sup>TM</sup>) on cell proliferation in her-2/neu (erbb2) positive breast cancer before surgery.

Total amount: 85.000 €

Sponsor: Regional Agency of Liguria, Genova-Italy; Italian League against Cancer (LILT), Roma-Italy;  
Carige Fondazione, Genova-Italy  
DeCensi (PI), 2006

- Phase I/II study of Allopurinol in Subjects with colorectal adenoma before polipectomy.

Total amount: 112.750 €

Sponsor: International Breast Cancer Study Group (IBCSG) Bern-Switzerland

DeCensi (PI), 2005-2008

- Investigating Bone Density and Bone Loss without Baseline Information” BIG1-98.Bone substudy.

Total amount: 96.400,00 €

Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy  
DeCensi (PI), 2005

- Second primary tumors: markers, etiology and predisposing factors.

Total amount: 120.000 €

Sponsor: Italian League against Cancer (LILT), Roma-Italy; Association for Cancer Research (AIRC),  
Milano-Italy; Popular Bank of Novara Foundation, Novara-Italy

DeCensi (PI), 2004

- A Biomarker phase II Trial Of Intermittent, Low Dose Bicalutamide In Subjects At High Risk For Prostate Cancer (Pre-Web Study)

Total amount: 270.000 €

Sponsor: Italian association for Cancer Research (AIRC), Milano-Italy; Italian League against Cancer  
(LILT), Roma-Italy  
DeCensi (PI), 2004

- Randomized window of opportunity trial of finasteride or low dose bicalutamide or placebo in men with prostate cancer before radical prostatectomy.

Total amount: 260.000 €

Sponsor: Italian Ministry of Health, Roma-Italy  
DeCensi (PI), 2002-2004

- Preclinical and clinical activity of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase, in ER

negative breast cancers

Total amount: 250.000,00 €

Sponsor: Italian League against Cancer (LILT), Roma-Italy

DeCensi (PI), 2002-2003

- Identification of cellular atypia by ductal lavage in patients at increased risk for breast cancer

Total amount: 145.000,00 €

Sponsor: Avon Foundation, New York

DeCensi (PI), 2002

- Cellular atypia and KI-67 in ductal lavage as risk biomarkers in patients at increased risk for breast cancer.

Total amount: 100.000 \$

Sponsor: Italian League against Cancer (LILT), Roma-Italy; Italian Foundation for Cancer Research (FIRC), Milano-Italy

DeCensi (PI), 2001-2003

- A Phase III Study of Hormone replacement therapy opposed by low dose tamoxifen: the HOT Study.

Total amount: 540.000,00 €

Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy

DeCensi (PI), 2001-2003

- Phase III trial of nimesulide for prevention of colorectal adenoma recurrence.

Total amount: 196.120,00 €

Sponsor: Susan G. Komen Breast Cancer Foundation, Dallas TX

DeCensi (PI), 2000-2002

- A biomarker trial of tamoxifen at low doses in HRT users

Total amount: 249.672 \$

Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy

DeCensi (PI), 1998-2001

- Modulation of ovarian cancer cell proliferation and apoptosis by fenretinide (4-HPR) in patients with ascites. A Phase I-II window of opportunity trial.

Total amount: L.210.000.000

Sponsor: Susan G. Komen Breast Cancer Foundation Dallas, TX

DeCensi (PI), 1998-2000

- Potential benefit of fenretinide, a vitamin A analog on HRT-induced breast cancer risk”

Total amount: 178.450,00 \$

Sponsor: National Institute of Health, National Cancer Institute(grant # CA 77188-01), Bethesda, MD

DeCensi (PI), 1997-2002

- Phase IIb biomarker trial of low dose tamoxifen and 4-HPR in early breast cancer.

Total amount: 1.303.460,00 \$

Sponsor: National Institute of Health, National Cancer Institute (grant # CA 72286-02), Bethesda, MD

DeCensi (CO-PI), 1997-2001

- IGF-I modulation by 4-HPR and breast cancer risk

Total amount: 630.750,00 \$

Sponsor: Italian Association for Cancer Research (AIRC), Milano-Italy; National Institute of Health, National Cancer Institute (grant # CA-56457), Bethesda, MD

DeCensi (PI) 1995-1997

- Modulation of DNA content flow cytometry by Fenretinide in superficial bladder tumors.

Grants: Lit 95.000.000- 293.000 \$

Sponsor: Association for Cancer Research (AIRC), Milano-Italy

DeCensi (Co-PI), 1995-1997

- Chemoprevention of breast cancer: tamoxifen, fenretinide and estrogen replacement therapy Lire

Total amount: Lit 300.000.000

Sponsor: Association for Cancer Research (AIRC), Milano-Italy

DeCensi (PI), 1992-1994

- Biological profile and toxicity of fenretinide in superficial bladder cancer

Total amount: Lit 120.000.000

## 10.2 ACADEMIC TRIALS, LOCAL PI

---

International Breast Cancer Study Group (IBCSG) Bern-Switzerland.

DeCensi (PI), 2010- on going follow-up

- A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer (SOLE Study - BIG 1-07).

Amount: 1500 € per patient

Patients enrolled: 13

University of Pennsylvania Medical Center, USA

DeCensi (PI for Italy), 2003-2005

- MRI and mammographic density as biological markers of breast cancer and tamoxifen response.

Total amount: (NIH grant # 1P01CA82707-01A1) 400.000\$

Cancer Research UK, London

DeCensi (PI for Italy), 2003-2008

- Prevention of breast cancer with anastrozole. The IBIS II study.

Total amount: UK 1.500 € per subject

Italian Ministry of Health, Roma-Italy

DeCensi (PI- Operative Unit), 2002-2004

- Endocrine-metabolic modulators of penetrance of familial cancer

Total amount: 168.000,00 €

INT Milano

DeCensi (PI- Operative Unit), 2006-2007

Demetra: a Retrospective Observational Study in Women with Her2 Metastatic Cancer treated with Trastuzumab.

Patients enrolled:38

AIFA (Agenzia Italiana del Farmaco) Italy

DeCensi (PI- Operative Unit) 2008-on-going

- TAILOR (TARceva Italian Lung Optimization tRIal) – Optimization of erlotinib for the treatment of patients with advanced non-small cell lung cancer: an itaian randomized trial”.

Patients enrolled:4

ISS (Istituto Superiore di Sanità) Italy

DeCensi (PI- Operative Unit) 2008-on-going

- Diagnostic surveillance on women with genetic risk breast cancer.

Patient enrolled: 10

University of Modena and Reggio Emilia,Italy

DeCensi (PI- Operative Unit) 2010-on going

With the Support of AIFA (Agenzia Italiana del Farmaco) Italy

- Short-her: multicentric randomized phase III trial of 2 different adjuvant chemotherapy regimens plus 3 vs 12 months of trastuzumab in her2 positive breast cancer patients.

Patients enrolled:4

IRST Meldola – Dr. Dino Amadori - With the Support of Italian Health Ministry

DeCensi (PI- Operative Unit) 2011-on going

- Androgen Receptors as targets for the treatment of estrogen and progesterin positive and negative breast cancer.

Patients enrolled: center activation is on going

Grant: 15.000€

National Cancer Institute, Naples, Italy

DeCensi (PI- Operative Unit) 2012- on going Follow-up

- A multicenter study in Patients with stage III-IV epithelial ovarian cancer treated with carboplatin/paclitaxel with bevacizumab: clinical and biological prognostic factors. (MITO-16 - MANGO-OV2)

Patients enrolled: 9

Grant: 1.500

National Cancer Institute, Naples, Italy

DeCensi (PI- Operative Unit) 2014 in activation

- A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line. (MITO-16b - MANGO-OV2b – ENGOT-ov 17)

Mario Negri Gynecologic Oncology Group – MaNGO

DeCensi (PI- Operative Unit) 2014-on going

- Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) *versus* Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

Patients enrolled: 6

## 10.2 INDUSTRY SPONSORED TRIALS, LOCAL PI

---

Pfizer Italia S.r.l.

DeCensi (PI), 1998(2004)-2012

- Project number: CTN-96OEXE031. Randomised, Double-blind Trial in Postmenopausal Women with Primary Breast Cancer Who Have Received Adjuvant Tamoxifen for 2-3 Years, Comparing Subsequent Adjuvant Exemestane Treatment with Further Tamoxifen.

Patients enrolled: 10

Grant: 15.000€

GlaxoSmithKline

DeCensi (PI), 2005-2012

- Project number: EGF30008. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer.

Patients enrolled: 3

Grant: 20.000€

Roche

DeCensi (PI), 2005-2007

- Project number: MO18024. First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.

Patients enrolled: 5

Grant: NA

Sanofi-Aventis

DeCensi (PI), 2006-2011

- Project number: XRP6976J/3501. A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD®- leuprolide acetate) in Combination with TAXOTERE® (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Therapy Followed by the Same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse After Radical Prostatectomy.

Patients enrolled: 3

Grant: 15.000€

Amgen

DeCensi (PI), 2007- on going Follow-up

- Project number: AMGEN 20060445. Impact A prospective observational study of neutropenia and anaemia management in subjects with solid tumours receiving myelotoxic chemotherapy.

Patients enrolled: 5

Grant: 5.000€

GlaxoSmithKline

DeCensi (PI), 2007-2010

- Project number: FRX106365. The INPACT study (Improving with Nadroparin the Prognosis in Advanced Cancer Treatment) – A randomized, controlled trial in patients with advanced malignancies of the lung, pancreas, or prostate.

Patients enrolled: 6

Grant: 25.000€

Roche

DeCensi (PI), 2008-2014

- Project number: BO20289 Beatrice. An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.

Patients enrolled: 4

Grant: 40.000€

Astra Zeneca

DeCensi (PI), 2008-2011

- Project number: D4320C00015. A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Once Daily Orally Administered ZD4054 10 mg in Non Metastatic Hormone-resistant Prostate Cancer Patients.

Patients enrolled: 2

Grant: 15.000€

Astra Zeneca

DeCensi (PI), 2008-2011

- Project number: D4320C00033. A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in Comparison with Docetaxel in Patients with Metastatic Hormone-resistant Prostate Cancer.

Patients enrolled: 6

Grant: 40.000€

Merck KGaA

DeCensi (PI), 2009-2012

- Project number: EMR 62240-506 .Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m<sup>2</sup> weekly and 500 mg/m<sup>2</sup> every two weeks maintenance therapy after platinum-based chemotherapy in combination with cetuximab as first-line treatment for subjects with advanced non-small cell lung cancer (NSCLC).

Patients enrolled: 1

Grant: 5.000€

Amgen

DeCensi (PI), 2010-ongoing Follow-up

- Project number:20090508. A Phase III, Randomized, Double Blind Trial Of Weekly Paclitaxel Plus Amg386 Or Placebo In Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian Primary Peritoneal Or Fallopian Tube Cancers.

Patients enrolled: 13

Grant: 88.000€

Roche

DeCensi (PI), 2011-ongoing Follow-up

- Project number: RO4876646. Global study to assess the addition of bevacizumab to carboplatin and paclitaxel as front-line Treatment of epithelial ovarian cancer, fallopian, Tube carcinoma or primary peritoneal carcinoma (MO22923)Bevacizumab.

Patients enrolled: 12

Grant: 30.000€

Roche

DeCensi (PI), 2011-2014

- Project number: ML25379 Avareg - Randomized, non comparative phase II trial with bevacizumab and fotemustine in the treatment of recurrent glioblastoma

Patients enrolled: 3

Grant: 10.000€

Roche

DeCensi (PI), 2014 ongoing Follow-up

- A two-part, randomized phase II, double-blind, multicentre trial assessing the efficacy and safety of pertuzumab in combination with standard chemotherapy vs. placebo plus standard chemotherapy in women with recurrent platinum resistant epithelial ovarian cancer and low HER3 mRNA expression (MO28113 – PENELOPE)

Patients enrolled: 2

Grant: 7.000€

## 11. Publication Statistics ISI

**Total papers: 195**

**Cumulative Impact Factor: 1243.87**

**Mean Impact Factor: 6,40**

**Papers as First/Last Author: 127**

**Mean IF as First/Last Author: 6.50**

**H-index: 43** (calculated with Anne-Wil Harzing's PoP software: Harzing, A.W. (2007) Publish or Perish.)

Num	Authors	Title	Publication	IF
195	Clavarezza M, Puntoni M, Gennari A, Paleari L, Provinciali N, D'amico M, DeCensi A.	Dual block with lapatinib and trastuzumab versus single agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials.	Clin Cancer Res. 2016 May 2. pii:clincanres.1881.2015. [Epub ahead of print]	8.722
194	Puntoni M, Petrerà M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.	PROGNOSTIC SIGNIFICANCE OF VEGF AFTER TWENTY YEAR FOLLOW-UP IN A RANDOMIZED TRIAL OF FENRETINIDE IN NON-MUSCLE INVASIVE BLADDER CANCER.	Cancer Prev Res (Phila). 2016 Apr 4. pii:canprevres.0345.2015.[Epub ahead of print]	4.44
193	Fujiwara K, Monk BJ, Lhommé C, Coleman RL, Brize A, Oaknin A, Ray-Coquard I, Fabbro M, Provencher D, Bamias A, Vergote I, DeCensi A, Zhang K, Vogl FD, Bach BA, Raspagliesi F.	Health-related Quality of Life in Women With Recurrent Ovarian Cancer Receiving Paclitaxel Plus Trebananib or Placebo (TRINOVA-1).	Ann Oncol. 2016 Mar 30. pii:mdw147. [Epub ahead of print] PubMed PMID: 27029706.	7.040
192	Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, Gandini S.	Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis.	Int J Cancer. 2016 Feb 24. doi: 10.1002/ijc.30062. [Epub ahead of print] PubMed PMID: 26916107	5.08
191	Lazzeroni M, DeCensi A.	Alternate dosing schedules for cancer chemopreventive agents	Semin Oncol. 2016 Feb;43(1):116-122. doi: 10.1053/j.seminoncol.2015.09.014. Epub 2015 Sep 7. Review. PubMed PMID: 26970130.	3.89
190	Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.	Repurposing old drugs to chemoprevention: the case of metformin.	Semin Oncol. 2016 Feb;43(1):123-133. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review. PubMed PMID: 26970131	3.89



189	Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, De Censi A, Bonanni B	A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients.	Cancer Prev Res (Phila). 2016 Feb 29. pii: canprevres.0311.2015. [Epub ahead of print] PubMed PMID: 26928670	4.44
188	Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.	A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.	Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123.	4.44
187	DeCensi A, Thorat MA, Bonanni B, Smith SG, Cuzick J.	Barriers to preventive therapy for breast and other major cancers and strategies to improve uptake.	Ecancermedicalsience. 2015 Nov 24;9:595. doi: 10.3332/ecancer.2015.595. eCollection 2015.	1.20
186	Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A.	PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.	Clin Oncol (R Coll Radiol). 2015 Dec 17. pii: S0936-6555(15)00443-4. [Epub ahead of print]	1.475
185	Provinciali N, Lazzeroni M, Cazzaniga M, Gorlero F, Dunn BK, DeCensi A.	Metformin: risk-benefit profile with a focus on cancer.	Expert Opin Drug Saf. 2015 Sep 11:1-13. [Epub ahead of print]	2.74
184	De Censi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.	EFFECT OF METFORMIN ON BREAST DUCTAL CARCINOMA IN SITU PROLIFERATION IN A RANDOMIZED PRE-SURGICAL TRIAL.	Cancer Prev Res (Phila). 2015 Aug 14. pii: canprevres.0048.2015. [Epub ahead of print]	5.27
183	Bruno S, Ledda B, Tenca C, Ravera S, Orengo AM, Mazzarello AN, Pesenti E, Casciaro S, Racchi O, Ghiotto F, Marini C, Sambuceti G, DeCensi A, Fais F.	Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.	Oncotarget. 2015 Jun 5. [Epub ahead of print]	6.627
182	Piccardo A, Puntoni M, Morbelli S, Massollo M, Bongioanni F, Paparo F, Altrinetti V, Gonella R, Gennari A, Iacozzi M, Sambuceti G, DeCensi A.	18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.	Nuklearmedizin. 2015 Jul 13;54(4). [Epub ahead of print]	1.494
181	Paparo F, Piccardo A, Bacigalupo L, Piccazzo R, Rollandi L, Galletto Pregliasco A, Filauro M, DeCensi A, Rollandi GA.	Multimodality fusion imaging in abdominal and pelvic malignancies: current applications and future perspectives.	Abdom Imaging. 2015 May 8. [Epub ahead of print]	1.730
180	Gennari A, Costa M, Puntoni M, Paleari L, De Censi A, Sormani MP, Provinciali N, Bruzzi P.	Breast cancer incidence after hormonal treatments for infertility: systematic review and meta-analysis of population-based studies.	Breast Cancer Res Treat. 2015 Mar 6. [Epub ahead of print] PubMed PMID: 25744295	4.469

179	Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B.	Long-term effects of inhaled budesonide on screening-detected lung nodules.	Ann Oncol. 2015 Feb 11. pii: mdv064. [Epub ahead of print]	6.578
178	Principi M, De Censi A.	Prevention of colorectal adenomas.	Colorectal Dis. 2015 Jan;17 Suppl 1:20-4..	2.415
177	D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrerà M, de Censi A.	An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.	Expert Opin Drug Saf. 2014 Sep 16:1-6. [Epub ahead of print]	2.735
176	DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.	Breast Cancer Res Treat. 2014 Sep 25. [Epub ahead of print]	4.469
175	Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E.	Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis taking into account Biases and Confounders.	Cancer Prev Res (Phila). 2014 Jul 1. pii: canprevres.0424.2013.	4.91
174	Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaoli A, Cantore M, Di Fabio F, Aitini E, Marchet A ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.	Ann Oncol. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12.	6.43
173	Smith T, Elwood P, Keating C, Rothwell P, Detering E, Freedman A, Langley R, Logan R, Phillips C, DeCensi A.	The Aspirin Foundation Scientific Conference: the history, the present state and the future of aspirin prophylaxis.	2014 Jan 24;8:388. doi: 10.3332/ecancer.2014.388. eCollection 2014.	N/A
172	Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S.	Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.	Breast Cancer Res Treat. 2014 Apr;144(2):321-9.	4.469
171	Gennari A, Nanni O, Puntoni M, DeCensi A, Scarpi E, Conte P, Antonucci G, Amadori D, Bruzzi P.	Body mass index and prognosis of metastatic breast cancer patients receiving first-line chemotherapy.	Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1862-7	4.559
170	Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A.	Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.	Breast Cancer Res Treat. 2013 Dec;142(3):569-78.	4.469

169	Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A.	Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.	Ann Oncol. 2013 Dec 18. [Epub ahead of print]	6,43
168	Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B.	The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer.	Br J Cancer. 2013 Nov 26;109(11):2792-7	5,04
167	Lazzeroni M, DeCensi A.	Breast cancer prevention by antihormones and other drugs: where do we stand?	Hematol Oncol Clin North Am. 2013 Aug;27(4):657-72	2.08
166	DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, Cazzaniga M, Lazzeroni M, Rotmensz N, Santillo B, Sideri M, Cassano E, Belloni C, Muraca M, Segnan N, Masullo P, Costa A, Monti N, Vella A, Bisanti L, D'Aiuto G, Veronesi U	Italian HOT Study Group. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study.	Ann Oncol. 2013 Nov;24(11):2753-60.	6,43
165	Garassino MC, Martelli O, Broggin M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	Lancet Oncol. 2013 Sep;14(10):981-8.	24.229.
164	Visvanathan K, Hurley P, Bantug E, Brown P, Col NF, Cuzick J, Davidson NE, Decensi A, Fabian C, Ford L, Garber J, Katapodi M, Kramer B, Morrow M, Parker B, Runowicz C, Vogel VG 3rd, Wade JL, Lippman SM.	Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.	J Clin Oncol. 2013 Aug 10;31(23):2942-62	18,37
163	Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri MT, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, Decensi A, Bonanni B.	A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.	Breast Cancer Res. 2013 Jun 20;15(3):R47.	5,25
162	Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, Lacroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL; for the SERM Chemoprevention of Breast Cancer Overview Group.	Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.	Lancet. 2013 May 25;381(9880):1827-34.	38,278
161	Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Castillo AD, Bassi F, Pagani G, Decensi A, Viale G, Bonanni B, Pruneri G.	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.	Br J Cancer. 2013 Apr 30;108(8):1593-601.	5,042

160	Dunn BK, Cazzaniga M, Decensi A.	Exemestane: One part of the chemopreventive spectrum for ER-positive breast cancer.	Breast. 2013 Jun;22(3):225-37.	2,491
159	Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, Decensi A.	Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.	Ann Oncol. 2013 Mar 26. [Epub ahead of print]	6,425
158	Puntoni M, Decensi A.	Allopurinol in subjects with colorectal adenoma--response.	Cancer Prev Res (Phila). 2013 Apr;6(4):369.	4,91
157	Gandini S, Guerrieri-Gonzaga A, Puntoni M, Decensi A.	Metformin and breast cancer risk.	J Clin Oncol. 2013 Mar 1;31(7):973-4.	18,372
156	Puntoni M, Branchi D, Argusti A, Zanardi S, Crosta C, Meroni E, Munizzi F, Michetti P, Coccia G, De Roberto G, Bandelloni R, Turbino L, Minetti E, Mori M, Salvi S, Boccardo S, Gatteschi B, Benelli R, Sonzogni A, DeCensi A.	A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma.	Cancer Prev Res (Phila). 2013 Feb;6(2):74-81.	4,908
155	Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A.	Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug.	Breast Cancer Res. 2012 Oct 29;14(5):214.	5,245
154	Bonelli L, Puntoni M, Gatteschi B, Massa P, Missale G, Munizzi F, Turbino L, Villanacci V, De Censi A, Bruzzi P.	Antioxidant supplement and long-term reduction of recurrent adenomas of the large bowel. A double-blind randomized Trial.	J Gastroenterol. 2012 Oct 13.	4,160
153	Defferrari C, Campora S, D'Amico M, Piccardo A, Biscaldi E, Rosselli D, Pasa A, Puntoni M, Gozza A, Gennari A, Zanardi S, Lionetto R, Bandelloni M, Decensi A.	A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer.	J Ovarian Res. 2012 Jun 25;5(1):17.	2,43
152	Simonato A, Varca V, Gacci M, Gontero P, De Cobelli O, Maffezzini M, Salvioni R, Carini M, Decensi A, Mirone V, Carmignani G.	Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study.	Adv Urol. 2012;2012:651061. Epub 2012 May 15.	2,428
151	Decensi A, Dunn BK, Puntoni M, Gennari A, Ford LG.	Exemestane for breast cancer prevention: a critical shift?	Cancer Discov. 2012 Jan;2(1):25-40	10,143
150	Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Stella Trabacca M, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial.	J Clin Oncol. 2012 Jul 20;30(21):2593-600	18,372
149	Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.	Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.	Breast Cancer Res Treat. 2012 Jul;134(2):693-700.	4,859

148	Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee.	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.	Lancet Oncol. 2012 Apr;13(4):420-32. Epub 2012 Jan 20.	22,589
147	Ghiorzo P, Pensotti V, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bonelli L, Borgonovo G, Bruno W, Gozza A, Gargiulo S, Mastracci L, Nasti S, Palmieri G, Papadia F, Pastorino L, Russo A, Savarino V, Varesco L, Bernard L, Bianchi Scarrà G; Genoa Pancreatic Cancer Study Group	Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy	Fam Cancer. 2012 Mar;11(1):41-7	2,139
146	Gennari A, Piccardo A, Altrinetti V, Corradengo D, Villavecchia G, De Censi A.	Whither the PET scan? The role of PET imaging in the staging and treatment of breast cancer.	Curr Oncol Rep. 2012 Feb;14(1):20-6.	2,400
145	Lazzeroni M, Gandini S, Puntoni M, Bonanni B, Gennari A, DeCensi A.	The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it	Breast. 2011 Oct;20 Suppl 3:S36-41	2,089
144	Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.	Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.	J Clin Oncol. 2012 Jan 10;30(2):151-7.	18,372
143	Piccardo A, Altrinetti V, Bacigalupo L, Puntoni M, Biscaldi E, Gozza A, Cabria M, Iacozzi M, Pasa A, Morbelli S, Villavecchia G, Decensi A	Detection of metastatic bone lesions in breast cancer patients: Fused (18)F-Fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience.	Eur J Radiol. 2012 Oct;81(10):2632-8.	2,941
142	Ghiorzo P, Fornarini G, Sciallero S, Battistuzzi L, Belli F, Bernard L, Bonelli L, Borgonovo G, Bruno W, De Cian F, Decensi A, Filauro M, Faravelli F, Gozza A, Gargiulo S, Mariette F, Nasti S, Pastorino L, Queirolo P, Savarino V, Varesco L, Scarrà GB; Genoa Pancreatic Cancer Study Group	CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.	J Med Genet. 2012 Mar;49(3):164-70	7,037
141	Rizzoli R, Body JJ, Decensi A, Reginster JY, Piscitelli P, Brandi ML; on behalf of the European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO)	Erratum to: Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.	Osteoporos Int. 2012 Mar 3	4,859
140	Decensi A, Pruneri G, Guerrieri-Gonzaga A.	Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?	J Clin Oncol. 2012 Apr 20;30(12):1384-6.	18,372
139	Bruno S, Ghiotto F, Tenca C, Mazzarello A, Bono M, Luzzi P, Casciaro S, Recchia A, Decensi A, Morabito F, Fais F	N-(4-hydroxyphenyl) retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates Fludarabine and ABT-737 cytotoxicity.	Leukemia. 2012 Apr 5.	9,561

138	Maisonneuve P, Bagnardi V, Bellomi M, Spaggiari L, Pelosi G, Rampinelli C, Bertolotti R, Rotmensch N, Field JK, Decensi A, Veronesi G.	Lung cancer risk prediction to select smokers for screening CT - A model based on the Italian COSMOS trial.	Cancer Prev Res (Phila). 2011 Aug 2. [Epub ahead of print]	5,983
137	Montironi R, Bartels PH, Decensi A, Puntoni M, Hurler R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, Alberts DS, Maffezzini M.	A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry	Urol Oncol. 2011 Jul 21. [Epub ahead of print]	3,172
136	Pelosi G, Rossi G, Bianchi F, Maisonneuve P, Galetta D, Sonzogni A, Veronesi G, Spaggiari L, Papotti M, Barbareschi M, Graziano P, Decensi A, Cavazza A, Viale G.	Immunohistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens.	J Thorac Oncol. 2011 Jun;6(6):1039-49.	4,040
135	Andrea DeCensi, Matteo Puntoni, Giancarlo Pruneri, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Davide Serrano, Debora Macis, Harriet Johansson, Oriana Pala, Alberto Luini, Paolo Veronesi, Viviana Galimberti, Maria Cristina Dotti, Giuseppe Viale and Bernardo Bonanni	Lapatinib Activity in Premalignant Lesions and HER-2-Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial.	Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. Epub 2011 Jun 17.	5,983
134	Gennari A, Stockler M, Puntoni M, Sormani M, Nanni O, Amadori D, Wilcken N, D'Amico M, Decensi A, Bruzzi P.	Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	J Clin Oncol. 2011 Jun 1;29(16):2144-9. Epub 2011 Apr 4. Review.	17,793
133	Cuzick J, Decensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H.	Preventive therapy for breast cancer: a consensus statement.	Lancet Oncol. 2011 May;12(5):496-503. Review.	14,47
132	Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B.	Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.	Cancer Prev Res (Phila). 2011 Jan;4(1):34-42. Epub 2010 Dec 16.	5,983
131	Decensi A, Gennari A.	Insulin Breast Cancer Connection: Confirmatory Data Set the Stage for Better Care	J Clin Oncol. 2011 Jan 1;29(1):7-10. Epub 2010 Nov 29.	17,793
130	Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S.	Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.	Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61. Epub 2010 Oct 12.	5,983
129	Decensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B.	Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.	Ann Oncol. 2010 Aug 17. [Epub ahead of print]	5,647
128	Serrano D, Lazzeroni M, Zamboni CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensch N, Decensi A, Bonanni B.	Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial	Pharmacogenomics J. 2010 Mar 23. [Epub ahead of print]	4,398

127	Macis D, Cazzaniga M, De Censi A, Bonanni B.	Role of traditional and new biomarkers in breast carcinogenesis.	Ecancermedicalseience. 2009;3:157. Epub 2009 Oct 29.	0,000
126	Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM).	Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey	Tumori. 2009 Nov-Dec;95(6):647-51.	0,863
125	Haugan Moi LL, Hauglid Flågå M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, De Censi A, Mellgren G.	Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue	Clin Cancer Res. 2010 Mar 23. [Epub ahead of print]	6,488
124	Sogno I, Venè R, Ferrari N, De Censi A, Imperatori A, Noonan DM, Tosetti F, Albini A.	Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies.	Crit Rev Oncol Hematol. 2009 Dec 22. [Epub ahead of print]	4,589
123	Morasso G, Di Leo S, Caruso A, Decensi A, Beccaro M, Berretta L, Bongiorno L, Cosimelli M, Finelli S, Rondanina G, Santoni W, Stigliano V, Costantini M.	Evaluation of a screening programme for psychological distress in cancer survivors.	Support Care Cancer. 2009 Nov 18.	2,422
122	Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.	Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.	Clin Cancer Res. 2009 Nov 15;15(22):7053-60. Epub 2009 Nov 3	6,488
121	Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.	Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.	Ann Oncol. 2009 Oct 25	4,935
120	Puntoni M, Decensi A.	The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.	Eur J Cancer. 2009 Sep;45 Suppl 1:346-54. Review.	4,475
119	Andrea Decensi, Chris Robertson, Aliana Guerrieri-Gonzaga, Davide Serrano, Massimiliano Cazzaniga, Serena Mora, Marcella Gulisano, Harriet Johansson, Viviana Galimberti, Enrico Cassano, Simona Moroni, Franca Formelli, Ernst Lien, Giuseppe Pelosi, Karen J	Randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women	J Clin Oncol. 2009 Aug 10;27(23):3749-56. Epub 2009 Jul 13.	17,157
118	Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne, G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.	Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 1x years	Oncologist. 2009 Mar;14(3):201-12.	6,630
117	Cazzaniga M, Decensi A, Bonanni B, Luini A, Gentilini O.	Biomarkers for risk assessment and prevention of breast cancer	Curr Cancer Drug Targets. 2009 Jun;9(4):482-99.	4,316
116	Massimiliano Cazzaniga, Bernardo Bonanni, Aliana Guerrieri-Gonzaga, Andrea Decensi	Is it time to test metformin in breast cancer clinical trials?	Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5	4,770
115	Zanardi S, Puntoni M, Maffezzini M, Bandelloni R, Mori M, Argusti A, Campodonico F, Turbino L, Branchi D, Montironi R, Decensi A	Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies	Cancer Prev Res (Phila Pa). 2009 Apr;2(4):377-84	5,983

114	Matteo Puntoni, Bernardo Bonanni, Andrea Decensi	Dietary changes after breast cancer in women without hot flashes: a simple and inexpensive way to target tumor and host?	J Clin Oncol. 2009 Jan 20;27(3):323-5	17,157
113	Harriet Johansson, Sara Gandini, Aliana Guerrieri-Gonzaga, Simona Iodice, Massimiliano Ruscica, Bernardo Bonanni, Marcella Gulisano, Paolo Magni, Franca Formelli, Andrea Decensi	Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer	Cancer Res. 2008 Nov 15;68(22):9512-8	7,514
112	Puntoni M, Marra D, Zanardi S, Decensi A	Inflammation and Cancer Prevention	Ann Oncol 2008 Sep;19 Suppl 7:vii225-9. Review	4,935
111	Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M	Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis	Breast Cancer Res Treat. 2009 Apr;114(3):599-605	5,684
110	Rondanina G, Puntoni M, Severi G, Varricchio C, Zumino A, Feroce I, Bonanni B, Decensi A	Psychological and Clinical Factors Implicated in Decision Making About a Trial of Low-Dose Tamoxifen in Hormone Replacement Therapy Users	J Clin Oncol, Vol 26, No 9 (March 20), 2008:1537-43	17,157
109	Serrano D, Gandini S, Mariani L, Bonanni B, Santinelli A, guerrieri-Gonzaga A, Pelosi G, Cassano E, Montironi R, Decensi A.	Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users	The Breast 2008 Feb; 17(1):91-7	2,155
108	Decensi A, Gandini S., Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B.	A randomized dose-ranging trial of Tamoxifen at low doses in hormone replacement therapy users.	J Clin Oncol 2007 Sep 20;25(27):4201-9.	13,598
107	Puntoni M, Zanardi S, Branchi D, Bruno S, Curotto A, Varaldo M, Bruzzi P, Decensi A.	Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.	Cancer Epidemiol Biomarkers Prev 2007 May;16(5):979-83.	4,289
106	Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Oliviero P, Lovison F, Gucciardo G, Rosselli del Turco M, Muraca M.G, Pizzichetta M.A, Conforti S, Decensi A, The Italian Tamoxifen Study G	Tamoxifen for the prevention of breast cancer: Late results of the Italian Randomized Tamoxifen Trial Among Women with Hysterectomy	J Natl Cancer Inst 2007 May 2;99(9):727-37.	15,271
105	Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A.	Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.	Breast Cancer Res Treat 2007 Apr 28; [Epub ahead of print]	4,671
104	Veronesi U, Maisonneuve P, Decensi A.	Tamoxifen: An Enduring Star	J Natl Cancer Inst 2007 Feb 21;99(4):258-60	15,271
103	Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, Santillo B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A.	Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.	Breast Cancer Res Treat 2007 Jan 27; [Epub ahead of print]	4,671
102	Decensi A, Zanardi S, Argusti A, Bonanni B, Costa A, Veronesi U.	Fenretinide and risk reduction of second breast cancer.	Nat Clin Pract Oncol. 2007 Feb;4(2):64-5.	5,364



101	Colombo N, Formelli F, Cantu MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A.	A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.	Cancer Epidemiol Biomarkers Prev 2006 Oct;15(10):1914-9.	4,289
100	Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU.	Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.	J Clin Oncol 2006 Aug 1;24(22):3708-9; author reply 3709.	13,598
99	M. Cazzaniga, G. Severi, C. Casadio, L. Chiapparini, U. Veronesi and A. Decensi.	Association between breast cancer risk and nipplefluid with atypia with or without ki 67 expression in ductal lavage. The Milan experience.	Cancer Epidemiol Biomarkers Prev 2006 Jul; 15(7): 1311-5.	4,289
98	U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, and G. De Palo.	Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer	Ann Oncol 2006 Jul; 17(7): 1065-71. epub 2006 May 4.	5,179
97	Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, Decensi A.	Clinical trials with retinoids for breast cancer chemoprevention	Endocr-Relat Cancer 2006 Mar; (13): 51-68.	4,763
96	Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A and Bonanni B.	Quality of life assessment in a chemoprevention trial fenretinide and HRT.	Maturitas 2006 Aug 20;55 (1) : 69-75. Epub 2006 Feb 24	1,947
95	Guerrieri-Gonzaga A, Robertson C, Bonanni B, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Intra M, Latronico A, Franchi D, Pelosi G, Johnson K, Decensi A.	Preliminary results of a randomized double-blind 2x2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women.	J Clin Oncol 2006 Jan 1; 24(1):129-135.	13,598
94	Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A.	Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal 5 women with primary breast cancer.	Breast Cancer Res Treat 2006 Jul; 98 (2) : 167-72. Epub 2006 Mar 15	4,671
93	Gasco M, Argusti A, Bonanni B, Decensi A.	SERMs in chemoprevention of breast cancer.	Eur J Cancer 2005 Sep;41(13):1980-9.	3,302
92	Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U.	Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 54x8 women enrolled in Italian tamoxifen chemoprevention trial.	BMJ 2005 Apr 23;330(7497):932	7,038
91	Serrano D, Baglietto L, Johansson H, Mariette F, Torrisi R, Onetto M, Paganuzzi M, Decensi A.	Effect of the synthetic retinoid fenretinide on circulating free prostate specific antigen, insulin-like growth factor-I and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.	Clin Cancer Res 2005 Mar 1;11(5):2083-8	5,623
90	Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, Salvioni A, Travaglini R, Oliviero P, D' Aiuto G, Gulisano M, Gucciardo G, Rosselli del Turco M, Pizzichetta MA, Conforti S, Bonanni B, Boyle P, Veronesi U for the Italian Tamoxifen Study	Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial.	Circulation 2005 Feb 8;111(5):650-6	12,563
89	Serrano D, Lazzeroni M, Decensi A.	Chemoprevention of colorectal cancer: an Update.	Tech Coloproctol. 2004 Dec;8 Suppl 2:s248-52. Review.	1,288

88	Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D, Serrano D, Sandri MT, Decensi A.	Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 74x women at risk for breast cancer.	Breast Cancer Res Treat 2004 Nov;88(1):63-73	2,975
87	Decensi A, Bonanni B, Baglietto L, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Robertson C, Marinucci I, Mariette F, Sandri MT, Daldoss C, Bianco V, Buttarelli M, Cazzaniga M, Franchi D, Cassano E, Omodei U.	A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.	Clin Cancer Res 2004 Jul 1;10(13):4389-97	5,623
86	Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA.	Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.	Clin Cancer Res 2004 Apr 1;10(7):2336-43	5,623
85	Serrano D, Perego E, Costa A, Decensi A.	Progress in chemoprevention of breast cancer.	Crit Rev Oncol Hematol 2004 Feb;49(2):109-17	2,667
84	Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri M.T, Mriette F, Lien E.A. And Decensi A.	Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women	J Thromb Haemost, 2003 1: 2149-2152	5,947
83	Veronesi U, Maisonneuve P, Rotmensz N, Decensi A, Viale G, Boyle P.	Re: Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women.	J Natl Cancer Inst 2003 June 18; 95 (12): 918-919	13,856
82	Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri Gonzaga A, Ramazzotti F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.	Re: Effect of transdermal estradiol and oral conjugated estrogen on c-reactive protein in retinoid placebo trial in healthy women.	Circulation 2003 May;107:e127-e128 (reply).	12,563
81	Serrano D, Bonanni B, Cazzaniga M, Galli A, Gonzaga AG, Decensi A.	Pharmacological prevention of breast cancer: quo vadis?	Breast 2003 Dec;12(6):379-86	0,760
80	Decensi A, Serrano D, Bonanni B, Cazzaniga M, Guerrieri-Gonzaga A.	Breast cancer prevention trials using retinoids.	J Mammary Gland Biol Neoplasia 2003 Jan;8(1):19-30	2,984
79	Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F.	Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.	Clin Cancer Res 2003 Oct 15;9(13):4722-9	5,623
78	Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L, Ponzoni M, Decensi A, De Bernardi B, Bellani FF, Formelli F.	Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.	Clin Cancer Res 2003 Jun;9(6):2032-9	5,623
77	Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER, Veronesi P, Torrissi R, Cazzaniga M, Mora S, Sandri MT, Pelosi G, Luini A, Goldhirsch A, Lien EA, Veronesi U.	A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers.	J Natl Cancer Inst 2003 Jun 4;95(11):779-90	13,856
76	Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Decensi A, Robertson C, Boyle P; Italian Tamoxifen Study Group.	Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women.	J Natl Cancer Inst 2003 Jan 15;95(2):160-5	13,856

75	Decensi A, Galli A, Veronesi U.	HRT opposed to low-dose tamoxifen (HOT study): rationale and design.	Recent Results Cancer Res. 2003;163:104-11; discussion 264-6. Review.	0,000
74	Rotmensz N, Decensi A, Maisonneuve P, Costa A, Sacchini V, Travaglini R, D'Aiuto G, Lovison F, Gucciardo G, Muraca MG, Pizzichetta MA, Conforti S, Robertson C, Boyle P, Veronesi U.	Rationale for a study adding tamoxifen to HRT.	Eur J Cancer 2002 Nov;38 Suppl 6:S22-3	3,302
73	Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P; Italian Tamoxifen Study Group (citato tra i membri).	Tamoxifen for breast cancer among hysterectomised women.	Lancet 2002 Mar 30;359(9312):1122-4	21,713
72	Decensi A.	[Risks and benefits of hormone replacement therapy: clinical considerations and research implications].	Epidemiol Prev. 2002 Nov-Dec;26(6):280-2. Italian	0,000
71	Decensi A, Omodei U, Robertson C, Bonanni B, Guerrieri-Gonzaga A, Ramazzotto F, Johansson H, Mora S, Sandri MT, Cazzaniga M, Franchi M, Pecorelli S.	Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.	Circulation 2002 Sep 3;106(10):1224-8	12,563
70	De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U.	Effect of fenretinide on ovarian carcinoma occurrence.	Gynecol Oncol 2002 Jul;86(1):24-7	2,083
69	Guerrieri-Gonzaga A, Galli A, Rotmensz N, Decensi A.	The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives.	Ann N Y Acad Sci 2001 Dec;949:113-22	1,789
68	Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Torrissi R, Sandri MT, Cazzaniga M, Mora S, Robertson C, Lien EA, Decensi A.	Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women.	Breast Cancer Res Treat 2001 Sep;69(1):21-7	3,310
67	Torrissi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A.	Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.	Br J Cancer 2001 Dec 14;85(12):1838-41	3,742
66	Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F.	Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.	Cancer Epidemiol Biomarkers Prev 2001 Oct;10(10):1047-53	4,500
65	Guerrieri-Gonzaga A, Baglietto L, Johansson H, Bonanni B, Robertson C, Sandri MT, Canigiula L, Lampreda C, Diani S, Lien EA, Decensi A.	Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial.	Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):967-70	4,500
64	Dowsett M, Bundred NJ, Decensi A, Sainsbury RC, Lu Y, Hills MJ, Cohen FJ, Veronesi P, O'Brien ME, Scott T, Muchmore DB.	Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.	Cancer Epidemiol Biomarkers Prev 2001 Sep;10(9):961-6	4,500
63	Torrissi R, Decensi A, Formelli F, Camerini T, De Palo G.	Chemoprevention of breast cancer with fenretinide.	Drugs 2001;61(7):909-18	4,412
62	Veronesi U, Decensi A.	Retinoids for ovarian cancer prevention: laboratory data set the stage for thoughtful clinical trials.	J Natl Cancer Inst 2001 Apr 4;93(7):486-8	13,856

61	Camerini T, Mariani L, De Palo G, Marubini E, Di Mauro MG, Decensi A, Costa A, Veronesi U.	Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.	J Clin Oncol 2001 Mar 15;19(6):1664-70	11,810
60	Baglietto L, Torrissi R, Arena G, Tosetti F, Gonzaga AG, Pasquetti W, Robertson C, Decensi A.	Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer.	Cancer Detect Prev 2000;24(4):369-75	1,408
59	Decensi A, Bonanni B, Rotmensz N, Robertson C, Guerrieri-Gonzaga A, Mora S, Diani S, Cazzaniga M, Costa A.	Update on tamoxifen to prevent breast cancer. The Italian Tamoxifen Prevention Study.	Eur J Cancer 2000 Sep;36 Suppl 4:S50-1	3,302
58	Decensi A, Torrissi R, Bruno S, Costantini M, Curotto A, Nicolo G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone WF, Bruzzi P.	Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.	Cancer Epidemiol Biomarkers Prev 2000 Oct;9(10):1071-8	4,500
57	Torrissi R, Mezzetti M, Johansson H, Barreca A, Pigatto F, Robertson C, Decensi A.	Time course of fenretinide-induced modulation of circulating insulin-like growth factor (IGF)-i, IGF-II and IGFBP-3 in a bladder cancer chemoprevention trial.	Int J Cancer 2000 Aug 15;87(4):601-5	4,416
56	Decensi A, Costa A.	Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer.	Eur J Cancer 2000 Apr;36(6):694-709	3,302
55	Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrissi R, Manetti L, Robertson C, De Palo G, Formelli F, Costa A, Veronesi U.	Chemoprevention of breast cancer: the Italian experience.	J Cell Biochem Suppl 2000;34:84-96	2,946
54	Veronesi U, De Palo G, Marubini E, Costa A, Mariani L, Formelli F, Decensi A.	Re: Vitamin A analogue for breast cancer prevention: a grade of F or incomplete?	J Natl Cancer Inst 2000 Feb 2;92(3):274; author reply 274-5	13,856
53	Bruno S, Torrissi R, Costantini M, Baglietto L, Fontana V, Gatteschi B, Melioli G, Nicolo G, Curotto A, Malcangi B, Bruttini GP, Varaldo M, Bruzzi P, Decensi A.	Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.	J Cell Biochem 1999 Dec;76(2):311-21	2,946
52	Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA.	Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.	J Clin Oncol 1999 Sep;17(9):2633-8	11,810
51	Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, Decensi A, Camerini T, Del Turco MR, Di Mauro MG, Muraca MG, Del Vecchio M, Pinto C, D'Aiuto G, Boni C, Campa T, Magni A, Miceli R, Perloff M, Malone WF, Sporn MB.	Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.	J Natl Cancer Inst 1999 Nov 3;91(21):1847-56	13,856
50	Decensi A, Robertson C, Ballardini B, Paggi D, Guerrieri-Gonzaga A, Bonanni B, Manetti L, Johansson H, Barreca A, Bettega D, Costa A.	Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women.	Eur J Cancer 1999 Apr;35(4):596-600	3,302
49	Decensi A, Torrissi R, Gozza A, Severi G, Bertelli G, Fontana V, Pensa F, Carozzo L, Traverso A, Milone S, Dini D, Costa A.	Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer.	Breast Cancer Res Treat 1999 Jan;53(2):145-51	2,975

48	Decensi A, Torrisci R, Fontana V, Barreca A, Ponzani P, Pensa F, Parodi S, Costa A.	Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial.	Eur J Cancer 1998 Jun;34(7):999-1003	3,302
47	Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U.	Biologic activity of tamoxifen at low doses in healthy women.	J Natl Cancer Inst 1998 Oct 7;90(19):1461-7	13,856
46	Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costa A, Veronesi U.	Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.	Br J Cancer 1998 Sep;78(5):572-8	3,742
45	Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P.	Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study (citato tra i membri).	Lancet 1998 Jul 11;352(9122):93-7	21,713
44	Fontana V, Decensi A, Orengo MA, Parodi S, Torrisci R, Puntoni R.	Socioeconomic status and survival of gastric cancer patients.	Eur J Cancer 1998 Mar;34(4):537-42	3,302
43	Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, Mannucci PM, Decensi A.	Tamoxifen reduces plasma homocysteine levels in healthy women.	Br J Cancer 1998 Jun;77(12):2264-6	3,742
42	Favoni RE, de Cupis A, Bruno S, Yee D, Ferrera A, Pirani P, Costa A, Decensi A.	Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.	Br J Cancer 1998 Jun;77(12):2138-47	3,742
41	Torrisci R, Parodi S, Fontana V, Pensa F, Casella C, Barreca A, De Palo G, Costa A, Decensi A.	Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.	Int J Cancer 1998 Jun 10;76(6):787-90	4,416
40	Costa A, Bonanni B, Manetti L, Guerrieri Gonzaga A, Torrisci R, Decensi A.	Prevention of breast cancer: focus on chemoprevention.	Recent Results Cancer Res. 1998;152:11-21.	0,000
39	De Palo G, Camerini T, Marubini E, Costa A, Formelli F, Del Vecchio M, Mariani L, Miceli R, Mascotti G, Magni A, Campa T, Di Mauro MG, Attili A, Maltoni C, Del Turco MR, Decensi A, D'Aiuto G, Veronesi U.	Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.	Tumori 1997 Nov-Dec;83(6):884-94	0,630
38	Decensi A, Fontana V, Fioretto M, Rondanina G, Torrisci R, Orengo MA, Costa A.	Long-term effects of fenretinide on retinal function.	Eur J Cancer 1997 Jan;33(1):80-4	3,302
37	Decensi A, Costa A.	Polyprenoic acid in hepatocellular carcinoma.	N Engl J Med 1996 Nov 7;335(19):1461; author reply 1461-2	38,570
36	Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A.	Effect of tamoxifen on endometrial proliferation.	J Clin Oncol 1996 Feb;14(2):434-40	9,835
35	Veronesi U, De Palo G, Costa A, Formelli F, Decensi A.	Chemoprevention of breast cancer with fenretinide.	IARC Sci Publ. 1996;(136):87-94. Review.	0,000
34	Bruno S, Machi AM, Semino C, Meta M, Ponte M, Varaldo M, Curotto A, Ferlazzo G, Decensi A, Melioli G.	Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer.	Cancer Immunol Immunother 1996 Jan;42(1):47-54	3,520

33	Costa A, De Palo G, Decensi A, Formelli F, Chiesa F, Nava M, Camerini T, Marubini E, Veronesi U.	Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.	Ann N Y Acad Sci 1995 Sep 30;768:148-62	1,789
32	Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG.	Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.	Cancer Res 1995 Feb 15;55(4):853-61	7,690
31	Torrise R, Pensa F, Fontana V, Costa A, Decensi A.	The metabolite N-4-methoxyphenylretinamide is a major determinant of fenretinide induced decline of plasma insulin-like growth factor-1.	Eur J Cancer 1995;31A(3):420-1	3,302
30	Torrise R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A.	Factors affecting plasma retinol decline during long-term administration of the synthetic retinoid fenretinide in breast cancer patients.	Cancer Epidemiol Biomarkers Prev 1994 Sep;3(6):507-10	4,500
29	Decensi A, Curotto A, Bruno S, Costantini M, Torrise R, Gatteschi B, Cussotto M, Pizzorno R, Quattrini S, Repetto U, Schenone M, Tentarelli T, Bruzzi P.	DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.	Eur J Cancer Prev 1994 Jul;3(4):377-9	1,785
28	Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U.	Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.	Cancer Res 1994 Apr 1;54(7 Suppl):2032s-2037s	7,690
27	Decensi A, Torrise R, Fontana V.	Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?	Br J Cancer 1994 Mar;69(3):617-9	3,742
26	Decensi AU, Formelli F, Torrise R, et al.	Fenretinide in breast cancer chemoprevention (review).	Oncology Rep 1: 817-24, 1994.	1,356
25	Decensi A, Bruno S, Costantini M, Torrise R, Curotto A, Gatteschi B, Nicolo G, Polizzi A, Perloff M, Malone WF.	Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.	J Natl Cancer Inst 1994 Jan 19;86(2):138-40	13,856
24	Decensi A, Torrise R, Polizzi A, Gesi R, Brezzo V, Rolando M, Rondanina G, Oregno MA, Formelli F, Costa A.	Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface.	J Natl Cancer Inst 1994 Jan 19;86(2):105-10.	13,856
23	Decensi A, Torrise R, Marroni P, Pensa F, Padovani P, Boccardo F.	Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.	Prostate 1994;24(1):17-23	4,331
22	Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F, Salvia G, Comeri G, Bono A, Borella T, Giuliani L.	Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.	J Clin Oncol 1994 Jan;12(1):7-13	11,810
21	Decensi A, Bruno S, Torrise R, Parodi S, Polizzi A.	Pilot study of high dose fenretinide and vitamin A supplementation in bladder cancer.	Eur J Cancer 1994;30A(12):1909-10	3,302
20	Torrise R, Pensa F, Oregno MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A.	The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.	Cancer Res 1993 Oct 15;53(20):4769-71	7,690

19	Decensi A, Torrisci R, Fontana V, Marroni P, Padovani P, Guarneri D, Minuto F, Boccardo F.	Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer.	Acta Endocrinol (Copenh) 1993 Oct;129(4):315-21	2,560
18	Costa A, Sacchini V, Decensi A.	Retinoids and tamoxifen in breast cancer chemoprevention.	Int J Clin Lab Res 1993;23(2):53-5	1,258
17	Boccardo F, Pace M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M, Delliponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G.	Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.	Eur J Cancer 1993;29A(8):1088-93	3,302
16	Decensi A, Formelli F, Torrisci R, Costa A.	Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints.	J Cell Biochem Suppl 1993;17G:226-33	2,946
15	Canobbio L, Guarneri D, Miglietta L, Decensi A, Oneto F, Boccardo F.	Carboplatin in advanced hormone refractory prostatic cancer patients.	Eur J Cancer 1993;29A(15):2094-6	3,302
14	Boccardo F, Guarneri D, Pace M, Decensi A, Oneto F, Martorana G.	Phase II study with lonidamine in the treatment of hormone-refractory prostatic cancer patients.	Tumori 1992 Apr 30;78(2):137-9	0,630
13	Decensi A, Bruno S, Giaretti W, Torrisci R, Curotto A, Gatteschi B, Geido E, Polizzi A, Costantini M, Bruzzi P, Nicolò G, Costa A, Boccardo F, Giuliani L, Santi L.	Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.	J Cell Biochem Suppl 1992;16I:139-47	2,946
12	Decensi AU, Boccardo F, Guarneri D, Positano N, Paoletti MC, Costantini M, Martorana G, Giuliani L.	Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.	J Urol 1991 Aug;146(2):377-81	3,713
11	Decensi A, Guarneri D, Paoletti MC, Lalanne JM, Merlo F, Boccardo F.	Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).	Eur J Cancer 1991;27(9):1100-4	3,302
10	Canobbio L, Boccardo F, Guarneri D, Calabria C, Decensi A, Curotto A, Martorana G, Giuliani L.	Phase II study of navelbine in advanced renal cell carcinoma.	Eur J Cancer 1991;27(6):804-5	3,562
9	Boccardo F, Decensi AU, Guarneri D, Martorana G, Fioretto L, Mini E, Macaluso MP, Giuliani L, Santi L, Periti P.	Anandron (RU 239x8) in metastatic prostate cancer: preliminary results of a multicentric Italian study.	Cancer Detect Prev 1991;15(6):501-3	1,408
8	Boccardo F, Canobbio L, Resasco M, Decensi AU, Pastorino G, Brema F.	Phase II study of tamoxifen and high-dose retinyl acetate in patients with advanced breast cancer.	J Cancer Res Clin Oncol 1990;116(5):503-6	2,409
7	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Oneto F, Martorana G, Giuliani L, Delli Ponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G.	Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).	Eur Urol 1990;18 Suppl 3:48-53	2,651
6	Decensi AU, Guarneri D, Marroni P, Di Cristina L, Paganuzzi M, Boccardo F.	Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing	J Urol 1989 Nov;142(5):1235-8	3,713

		hormone agonist in elderly men.		
5	Boccardo F, Decensi A, Guarneri D, Martorana G, Giberti C, Giuliani L.	Estramustine phosphate (estracyt) following androgens in men with refractory stage D2 prostate cancer.	Cancer Chemother Pharmacol 1988;22(2):172-4	2,216
4	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Martorana G, Giberti C, Cerruti GB, Tani F, Zanollo A, Germinale T, Borzone C, Perri F, Usai E, Santi L, Giuliani L.	Long-acting (depot) D-TRP-6 LH-RH (Decapeptyl) in prostate cancer. An Italian multicentric trial.	Am J Clin Oncol 1988;11 Suppl 2:S129-31	1,703
3	Boccardo F, Decensi A, Guarneri D, Rubagotti A, Massa T, Martorana G, Giberti C, Cerruti GB, Tani F, Zanollo A, Germinale T, Borzone C, Perri F, Usai E, santi L, Giuliani L.	Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.C.A.P.) study.	Prostate 1987;11(3):243-55	4,330
2	Robustelli della Cuna G, Zanon P, Pavese L, Preti P, Prada GA, Decensi A.	An overview of clinical trials with high-dose medroxyprogesterone acetate. (HD-MPA) in endocrine-related tumors other than breast cancer.	Chemioterapia 1986 Jun;5(3):164-72	1,248
1	Decensi A, Guarneri D, Boccardo F.	[Medullary carcinoma of the thyroid. Natural history, diagnosis and therapy].	Minerva Med. 1986 Nov 17;77(44):2131-5. Italian.	0,904

May 16, 2016

Dr. Andrea De Censi

